A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
Fiche publication
Date publication
mars 2023
Journal
Expert review of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Vieujean S, Louis E, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Ustekinumab is a humanized monoclonal antibody, targeting the p40 subunit common to both human interleukin 12 and 23, approved by the European Medicines Agency and US Food and Drug Administration for the treatment of moderate-to-severe ulcerative colitis.
Mots clés
UNIFI, efficacy, real-world studies, safety, ulcerative colitis, ustekinumab
Référence
Expert Rev Gastroenterol Hepatol. 2023 03 22;: